High-dose 131I-metaiodobenzylguanidine therapy in patients with high-risk neuroblastoma in Japan

被引：0
|
作者：
Daiki Kayano
Hiroshi Wakabayashi
Kenichi Nakajima
Rie Kuroda
Satoru Watanabe
Anri Inaki
Ayane Toratani
Norihito Akatani
Takafumi Yamase
Yuji Kunita
Tomo Hiromasa
Aki Takata
Hiroshi Mori
Shintaro Saito
Raita Araki
Junichi Taki
Seigo Kinuya
机构：
[1] Kanazawa University,Department of Nuclear Medicine, Kanazawa University Hospital and Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Science
[2] Kanazawa University,Department of Functional Imaging and Artificial Intelligence
[3] Kanazawa University,Department of Pediatrics, Kanazawa University Hospital and Department of Pediatrics, Institute of Medical, Pharmaceutical and Health Science
[4] Kanazawa Medical University,Department of Radiology
[5] Ishikawa Prefectural Central Hospital,Department of Pediatrics
来源：
Annals of Nuclear Medicine | 2020年 / 34卷
关键词：
I-metaiodobenzylguanidine; Refractory neuroblastoma; Relapsed neuroblastoma; Internal radiation therapy; Radionuclide therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：397 / 406
页数：9
相关论文
共 50 条
  • [1] High-dose 131I-metaiodobenzylguanidine therapy in patients with high-risk neuroblastoma in Japan
    Kayano, Daiki
    Wakabayashi, Hiroshi
    Nakajima, Kenichi
    Kuroda, Rie
    Watanabe, Satoru
    Inaki, Anri
    Toratani, Ayane
    Akatani, Norihito
    Yamase, Takafumi
    Kunita, Yuji
    Hiromasa, Tomo
    Takata, Aki
    Mori, Hiroshi
    Saito, Shintaro
    Araki, Raita
    Taki, Junichi
    Kinuya, Seigo
    ANNALS OF NUCLEAR MEDICINE, 2020, 34 (06) : 397 - 406
  • [2] High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma
    Rose, B
    Matthay, KK
    Price, D
    Huberty, J
    Klencke, B
    Norton, JA
    Fitzgerald, PA
    CANCER, 2003, 98 (02) : 239 - 248
  • [3] Thyroid and Hepatic Function After High-Dose 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Neuroblastoma
    Quach, Alekist
    Ji, Lingyun
    Mishra, Vikash
    Sznewajs, Aimee
    Veatch, Janet
    Huberty, John
    Franc, Benjamin
    Sposto, Richard
    Groshen, Susan
    Wei, Denice
    Fitzgerald, Paul
    Maris, John M.
    Yanik, Gregory
    Hawkins, Randall A.
    Villablanca, Judith G.
    Matthay, Katherine K.
    PEDIATRIC BLOOD & CANCER, 2011, 56 (02) : 191 - 201
  • [4] The Impact of 131I-Metaiodobenzylguanidine as a Conditioning Regimen of Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma
    Park, Hyun Jin
    Choi, Jung Yoon
    Kim, Bo Kyung
    Hong, Kyung Taek
    Kim, Hyun-Young
    Kim, Il Han
    Cheon, Gi Jeong
    Cheon, Jung-Eun
    Park, Sung-Hye
    Kang, Hyoung Jin
    CHILDREN-BASEL, 2023, 10 (12):
  • [5] Effectiveness of high-dose 131I-MIBG as consolidation therapy for the patients with high-risk neuroblastoma
    Inaki, A.
    Kuroda, R.
    Wakabayashi, H.
    Akatani, N.
    Yamase, T.
    Kunita, Y.
    Watanabe, S.
    Hiromasa, T.
    Mori, H.
    Saito, S.
    Ikawa, Y.
    Kayano, D.
    Kinuya, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S279 - S279
  • [6] Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study
    Ji Won Lee
    Sanghoon Lee
    Hee Won Cho
    Youngeun Ma
    Keon Hee Yoo
    Ki Woong Sung
    Hong Hoe Koo
    Eun Joo Cho
    Suk-Koo Lee
    Do Hoon Lim
    Journal of Hematology & Oncology, 10
  • [7] Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study
    Lee, Ji Won EUIS
    Lee, Sanghoon
    Cho, Hee Won
    Ma, Youngeun
    Yoo, Keon Hee
    Sung, Ki Woong
    Koo, Hong Hoe
    Cho, Eun Joo
    Lee, Suk-Koo
    Lim, Do Hoon
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
  • [8] Dosimetry-based high-activity therapy with 131I-metaiodobenzylguanidine (131I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma
    Jose Genolla
    Trinidad Rodriguez
    Pablo Minguez
    Ricardo Lopez-Almaraz
    Veronica Llorens
    Aizpea Echebarria
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1567 - 1575
  • [9] Dosimetry-based high-activity therapy with 131I-metaiodobenzylguanidine (131I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma
    Genolla, Jose
    Rodriguez, Trinidad
    Minguez, Pablo
    Lopez-Almaraz, Ricardo
    Llorens, Veronica
    Echebarria, Aizpea
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (07) : 1567 - 1575
  • [10] 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma
    Dubois, S. G.
    Matthay, K. K.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 57 (01): : 53 - 65
12345